Lupin completed the acquisition of five legacy brands from Menarini for $12.27m.

Lupin, a multinational pharmaceutical company, completed the acquisition of five legacy brands from Menarini, a biopharmaceutical company for $12.27m. “This acquisition aligns well with our strategic goal to broaden our presence in the Indian market. By offering a comprehensive range of products, our aim is to deliver even greater value to our stakeholders and the communities we serve,” Nilesh Gupta, Lupin Managing Director.